These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31350254)

  • 1. Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study.
    Lexchin J
    BMJ Open; 2019 Jul; 9(7):e030750. PubMed ID: 31350254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations.
    Jenei K; Meyers DE
    BMJ Open; 2023 Oct; 13(10):e066378. PubMed ID: 37844982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study.
    Lexchin J
    PLoS One; 2019; 14(2):e0212399. PubMed ID: 30768629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada.
    Meyers DE; Jenei K; Chisamore TM; Gyawali B
    JAMA Intern Med; 2021 Apr; 181(4):499-508. PubMed ID: 33616606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conditional approval of cancer drugs in Canada: accountability and impact on public funding.
    Andersen SK; Penner N; Chambers A; Trudeau ME; Chan KKW; Cheung MC
    Curr Oncol; 2019 Feb; 26(1):e100-e105. PubMed ID: 30853815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review.
    Raymakers AJN; Regier DA; Peacock SJ
    Cancer; 2020 Jan; 126(1):148-155. PubMed ID: 31544234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of rarity on Canadian oncology health technology assessment and funding.
    Keech J; Dai WF; Trudeau M; Mercer RE; Naipaul R; Wright FC; Ferguson SE; Darling G; Gavura S; Eisen A; Kouroukis CT; Beca J; Chan KKW
    Int J Technol Assess Health Care; 2020 Aug; ():1-6. PubMed ID: 32779560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of the Cancer Drug Funding Process in Canada.
    Gotfrit J; Jackson A; Shin JJW; Stewart DJ; Mallick R; Wheatley-Price P
    Curr Oncol; 2022 Mar; 29(3):1997-2007. PubMed ID: 35323362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
    Niraula S; Nugent Z
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
    [No Abstract]   [Full Text] [Related]  

  • 10. Are We Making a Difference? A Qualitative Study of Patient Engagement at the pan-Canadian Oncology Drug Review: Perspectives of Patient Groups.
    Mercer RE; Chambers A; Mai H; McDonald V; McMahon C; Chan KKW
    Value Health; 2020 Sep; 23(9):1157-1162. PubMed ID: 32940233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis.
    Lexchin J
    BMJ Open; 2017 Oct; 7(10):e018372. PubMed ID: 29061631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examining the association between oncology drug clinical benefit and the time to public reimbursement.
    Thomson S; Everest L; Witzke N; Jiao T; Delos Santos S; Nguyen V; Cheung MC; Chan KKW
    Cancer Med; 2022 Jan; 11(2):380-391. PubMed ID: 34850587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategizing health technology assessment for containment of cancer drug costs in a universal health care system: Case of the pan-Canadian Oncology Drug Review.
    Niraula S
    Cancer; 2019 Sep; 125(18):3100-3103. PubMed ID: 31154671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value-based pricing: Toward achieving a balance between individual and population gains in health benefits.
    Parmar A; Jiao T; Saluja R; Chan KKW
    Cancer Med; 2020 Jan; 9(1):94-103. PubMed ID: 31711274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR).
    Masucci L; Beca J; Sabharwal M; Hoch JS
    Pharmacoecon Open; 2017 Dec; 1(4):255-263. PubMed ID: 29441502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reporting of financial conflicts of interest in clinical practice guidelines: a case study analysis of guidelines from the Canadian Medical Association Infobase.
    Shnier A; Lexchin J; Romero M; Brown K
    BMC Health Serv Res; 2016 Aug; 16(a):383. PubMed ID: 27528247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the pan-Canadian Oncology Drug Review on provincial concordance with respect to cancer drug funding decisions and time to funding.
    Srikanthan A; Mai H; Penner N; Amir E; Laupacis A; Sabharwal M; Chan KKW
    Curr Oncol; 2017 Oct; 24(5):295-301. PubMed ID: 29089796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs.
    Saluja R; Jiao T; Koshy L; Cheung M; Chan KKW
    Curr Oncol; 2021 Jan; 28(1):606-618. PubMed ID: 33498460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011-2017.
    Skedgel C; Wranik D; Hu M
    Pharmacoeconomics; 2018 Apr; 36(4):467-475. PubMed ID: 29353385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the reasons for provincial discordance in cancer drug funding-a survey of policymakers.
    Srikanthan A; Penner N; Chan KKW; Sabharwal M; Grill A
    Curr Oncol; 2018 Aug; 25(4):257-261. PubMed ID: 30111966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.